The aim of the study was to evaluate the efficacy and safety of rosuvastatin in combination with fenofibric acid in a group of patients treated for 12 weeks with rosuvastatin 10 mg + fenofibric acid 135 mg and consequently treated for up to 52 weeks with rosuvastatin 20 mg + fenofibric acid 135 mg. The patients included in the study were men and women ≥18 years of age with mixed dyslipidemia, determined as TG ≥150 mg/dL, LDL-C ≥130 mg/dL, and HDL-C <40>
The investigators therefore concluded that combination therapy with rosuvastatin and fenofibric acid was well tolerated and raising the rosuvastatin dose from 10 mg to 20 mg in the combination results in further beneficial effects on key lipid parameters in patients with mixed dyslipidemia.
Source: Ferdinand KC, Davidson MH, Kelly MT, Setze CM. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response. Am J Cardiovasc Drugs. 2012 Apr 1;12(2):117-25.